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ABSTRACT The current difficulty in visuallzing the true extent of 
malignant brain tumors during surgkal rese<tlon represents one of 
the major reasons for the poor prognosis of brain tumor patients. 
Here, we evaluated the ability of a hand-held Raman sanner, 
guided by surfa<Hnhanced Raman sattering (SERS) nanopartldes, 
to identify the miaoscopic tumor extent in a geoeti<ally engineered 
RCAS/tv·a glioblastoma mouse model. ln a simulated intraoperative 
S<enario, we tested both a static Raman imaglng device and a 
mobile, hand-held Ra man scanner. We show that SERS lmage-guided resectlon ls more accurate than resection using white light visualization alone. 8oth 
methods complemented ea<h other, and correlation wlth hlstology showed that SERS nanopartides accurately outlined the extent of the turnors. 
lmportantly, the hand-held Raman probe not only anowed near real-time sanning, but also detected additional miaOS<opk fod of cancer in the rese<tlon 
bed that were notseenon statk SERS Imagesand would otherwise have been missed. This technology has a strong potential for dinical translation because 
it uses inert gold- silica SERS nanopartldes and a hand-held Raman scanner that can guide braln tumor resection in the operating room. 
KEYWORDS: surface-enhanced Raman scattering (SERS) · SERS nanoparticles • SER5-guided tumor resection • hand-held Raman 
scanner · brain tumors • glioblastoma multiforme • GBM 
The treatment of malignant bra in tumors, in particular glioblastoma multiforme (GBM) (= WHO grade IV 
astrocytoma), remains one of the greatest 
challenges in oncology, with an average 
mean survival for GBM patients of only 
12- 15 months.•.2 Surgery remains a main-
stay in the treatment of brain tumors, be-
cause tumor resections improve patient 
surviva13 6 and because the extent of resec-
tion (percentage of tumor removed) of both 
primary and recurrent tumors directly corre-
lates with the length of survival .~.6-s Most 
importantly, studies examining pattems of 
brain tumor recurrence have consistently 
shown that 80- 90% of recurrences are with-
in the original treatment field, indicating that 
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the cause are residual tumor cells left behind 
due to incomplete tumor resections.9•10 How-
ever, neurosurgeons are currently hindered in 
achieving complete resections because of 
indistinct tumor margins and miaoscopic 
tumor infiltrating several centimeters into 
the surrounding brain, which is impossible to 
detect with currently available methods.11 
Therefore, there is a critical unmet need for a 
method that enables discrimination of tumor 
from surrounding normal brain structl.Jres with 
microscopic predsion in the Operating room. 
Among the different malignant brain tu-
mor types, we have chosen GBM because 
these tumors are considered the most chat-
tenging to resect due to the diffuse pattern 
of tumor spread. lt has been shown that the 
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estimate of gross tumor burden reduction by neuro-
surgeons is much less accurate than postoperative 
modem neuroimaging assessments.12•13 Different ima-
ging techniques are currently being utilized to better 
visualize tumor margins. Presurgical magnetic resonance 
imaging (MRI) is used to plan stereotactic surgery and 
detemline the macroscopic outline of the tumor.1•·15 
Several studies have suggested that MRI using FLAIR, 
diffusion-weighted and n-weighted sequences is also 
able to image infiltrative microscopic tumor spread.1&.17 
However, the assessment of tumor borders by preopera-
tive MRI is often incongruent with the actual tumor 
borders during surgery due to brain shift during the 
operative procedure.1" 18 Intraoperative MRI is also lim-
ited by the necessity for frequent administrations of 
gadolinium (Gd)-<helates because of their short blood 
half-lives, 19 and by the inaccurades of fatse-positive 
cantrast enhancement 20 Smatl molecule Gd-agents dis-
perse from the Initial area of tumor enhancement into 
the peritumorat zone d edema over time, therefore 
causing inaccuracies in estimating the true tumor 
borders.21 Ultrasonography is being used at several 
centers and has been reported to improve patient 
outcome,2l.ll but cannot visualize microscopic cancer. 
Severat optical methods have been suggested, either 
based on intrinsic tissue optical properties11.24.2S or on 
exogenaus cantrast agents.1•..26 29 However, these op-
tical techniques often are limited by smatl fields of view 
(microscopy), deaeased speciflcity due to autofluores-
cence, or rapid photobleaching. These and other factors 
Iimit their potential to locatize the true extent of the 
tumor in a dinicat scenario:303 1 
We have recently reported, using a static surface-
enhanced Raman scattering (SERS) imaging micro-
scope, that suitable SERS nanoparticles can serve as 
an image-guidance tool and hetp in identifying mlcro-
scopic tumor in implanted glioma mause models.1• 
While real-time SERS imaging in the operating room 
would be highly desirable, it is not currently possible 
as rapid wide-field SERS imaging devices have not yet 
been developed. To address thls Iimitation, we have 
developed an intraoperative tumor detection method 
that could be applied dinicatly in the near future. We 
assessed the feasibility of a novet combination of static 
SERS imaging and near real-time SERS nanoparticle 
detection using a hand-held Raman scanner, in an 
intraoperative scenario. This was accomplished in a 
genetic mause model that closely mirnies the pathol-
ogy of human GBM. We found that static SERS imaging 
serves as an excetlent lmage-guidance tool for tumor 
resection, even in this infiltrative GBM model. lmpor-
tantly, we found that a hand-held Raman scanner 
could be used to scan, in near real-time, the resection 
bed for any residual microscopic tumor foci, especiatly 
in areas that could not be reached via static SERS 
imaging. Doing so, we identified microscopic foci at 
the resection margins that would have been missed 
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with static SERS imaging alone. After tumor resection 
was completed with this method, without requiring 
wide safety margins, no residual GBM tumor cetls were 
left in the resection bed as confirmed by histological 
methods. Given that the SERS nanoparticles used in 
this study have passed extensive cytotoxicity studies12 
and the hand-held Raman scanner tested here is 
already used in clinical trials for detection of intrinsic 
Raman spectra,33 this tumor-detection method has a 
strong potential for clinical translation and testing. 
RESULTS 
Stucly Design. Our study induded three different 
groups (n = 5 mice each) using different methods of 
brain tumor resection. We used the genetically engi-
neered GBM mouse model (PDGF-driven gliomas using 
RCAS/tv-a).~ which is known to mirnie human glioblas-
tomas very closely at a histologicallevel. 3S- l7 Four weeks 
after RCAS-injection, mouse brains were imaged by 
in vivo T2-weighted MRI to determine tumor size and 
location. Fifteen GBM bearing mice were selected via MRI 
saeening. All mice had tumors of similar size (diameter 
of 2- 5 mm), and were injected with gold- silica SERS 
nanoparticles (Figure 1 A- Q via tail vein (150 Jll volume, 
28.0 nM SERS nanopartide concentration). 
The particles were allowed to circulate for 24 h to 
ensure that they accumulated in the tumors. Mouse 
brains were then harvested, fixed in 4% paraformalde-
hyde, and randomly divided into 3 groups (see study 
design in Figure 2): (i) "Resection without Raman gui-
dance•, where tumor resection was only based on white 
light illumination; (iij "Resection with guidance by Ra-
man microscope", using static SERS imaging (Raman 
microscope, Figure 1 0), followed by hand-l'leld SERS 
scanning (Figure lE; to confirm the completeness of 
resection); and (ili) "Resection with guidance by hand-
held Raman scanner", where only the hand-held 
Raman scannerwas used to guide the tumor resection. 
ln groups (iij and (iii), both static SERS imaging and 
hand-held SERS scanning were used in order to cross-
validate the methods. 
(i). Resection without Roman Guidance. See Sup-
porting Information (Figure S1). 
(ii). Roman Microscope lmaging-Guided Tumor Re-
section. The brains (n = 5) were scanned utilizing the 
Raman microscope (fixed 90° angle of illumination). 
Raman images depicted the outline of tumors 
(Figure 3B 1 ), whlch correlated in location with the 
abnormality seen with white light illumination 
(Figure 3A 1 ). The presence of SERS-active Ra man 
foci was confirmed with a second scan with the Raman 
hand-held probe at a 90° angle, which also detected the 
5ERS spectrum of the SERS nanopartides at the same foci 
(Ftgure 3C1 ). Surgical removal of the Ra man positive area 
on the SERS imagewas performed next (FKJure 3A2), with 
acquisition of 5ERS images (Figure 362) between each 
resection step. The Ra man positive foci detected with the 
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Flgure 1. {A) Diagram of the SERS-nanopartlde design. deplctlng the gold core, Raman reporter layer (4,4' -dipyrldyl), and 
dye-encapsulating sllica shell. (8) Transmission electron mlaoscopy Images of the SERS nanopartkles. (0 Unique Raman 
"fingerprlnt" spectrum of the SERS nanopartkles (acquisition time =1 s, 1 00 mW Iaser power). (D) Raman mkroscope used to 
acqulre Images in this study (adjacent schematlc serves as the symbol for the miaoscope in the remalning figures). {E) Hand· 
held Raman scanner (adjacent schematk serves as the symbol for the microscope in the remainlng tigures). 
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Hoslology 
SERS microscope were then probed with the hand-held 
Raman scanner at the same 9QO angle, which detected 
the slgnature of our SERS nanopartides in the same 
locations (Figures 30). After these Raman positive 
foci were resected, the tumor beds were reimaged with 
the Raman mk roscope, with no residual Raman slgnal 
detected (Figure 3B3). Similar scanning with the hand-
held Ra man scannerat 90" angle did not reveal any SERS 
nanoparticle spectra either (Figure 3C3). 
KARABEBER ET AL. 
We hypothesized that small foci of tumor in the 
lateral margins of the resection bed can remain un-
detected if scanning is only performed using a 90" 
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Flgure 3. G8M resectlon with guidance by Raman mlaoscope. (A) Photographs of the lntact braln before (Al) and after 
(A2 and A3) successlve tumor resectlons gulded by the Raman mlaoscope (fixed 90• angle). When the hand-held Raman 
scanner was used at variable angles after these resection steps, additional mkroscopk tumor tissue was detected (location 
depicted by arrowhead ln A4). (8) SERS Images acquired wlth the Raman mlcroscope before (81) and after (82 and 83) 
successive tumor resections. (Cl The hand-held Ra manscannerwas used for verificatlon of slgnal (Cl C3) observed with the 
Raman mkroscope (81 83). (C4) Angulated scanning of the lateral wall of the resection bed with the hand-held Raman 
scanner detected mlcroscopic tumor, which had been missed by the Raman mkroscope. nssue was left in place for 
hlstologlcal verification in sltu (red Raman spectra = nanopartides detected ln brain tissue; blue Raman spectra = SERS 
nanoparttele standard as control). 
angle, due to overtying normal brain tlssue attenuating 
the Iaser beam (Figure 383,0). We therefore pro-
ceeded to rescan the resection bed with the hand-
held scanner by tilting the probe at variable angles 
to assess the lateral walls of the resection bed. lndeed, 
we observed residual Raman positive focl along the 
lateral margins that were previously undetected by 
lmaging at 90° (Figure 3C4). We marked the locations 
of these Ra man actlve foci without resecting them, in 
order to be able to histologically confirm them in situ. 
Histology demonstrated microscopic extensions of 
tumor lnto the surrounding brain tissue at these loca-
tions (Figure 4). 
(iii). Hand-Held Roman Sconner-Guided Tumor Re-
section. Experiments were performed in the same 
fashion as in group (II), except that the Ra man positive 
focl that were detected with the hand-held Raman 
scanner using variable angle scanning (Figure SC4) were 
surgically resected. Thls was followed by rescanning of 
KARA8E8ER ET AL. 
the resection bed with the hand-held scanner until no 
residual Raman positive fod were detected (Figure SC5). 
Histological processing of the resection bed revealed no 
residual tumor cells (Figure 6). 
These experiments demoostrate that small foci of 
residual Ra man signal can be detected with the hand-
held Raman scanner that are otherwise undetectable 
with fixed angle SERS imaging. We conclude that this is 
due to the ability of the surgeon to change the Ra man 
hand-held probe angle to reach out to detect other-
wise obscured Raman positive foci in the resection bed. 
Figure 7 shows a representative example of tumor 
tissue detected only with the hand-held scanner. The 
tissue that was detected with the angulated hand-held 
Ra man scanner (Figure 7 A) and subsequently resected 
(Figure 78,0) demonstrated the presence of the SERS 
nanoparticle Raman signature (Figure 70 that was 
confirmed tobe tumor by Iransmission electron micro-
scopy (TEM) and histology. TEM showed the presence 
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Figur~ 4. GBM resectlonwlth guldance by Ra man mlcroscopeand hlstologkal valldation. (Al T2-welghted brain MRI, showlog 
a mass in the right frontal lobe. (B) White light photograph of the intact brain befor~ resectlon, showing a d lscoloratlon in the 
area of the braln tumor corr~sponding in locatlon to th~ MRI. (C) Photograph of the tumor bed after resectlon based on the 
Raman mlcroscope Images. (D) Cranlal (top) to caudal (bottom) H&E stalned hlstology Images of axial braln sectlons alter 
completlon of surgery. 01 - 0 3 depict healthy braln tlssue on the medial (01 ) and posterlor (02) walls of the resection bed, 
whlle residual tumorwas present on the lateral (03) wall of the tumor on deeper sectlons (insets represent lmmunohlsto-
chemlcal staining with antl-<>lig-2 antlbody). 
of SERS nanopartides within the resected specimen 
(Figure 7E). H&E and immunohistochemical staining 
for the tumor marker OUg-2 confirmed that the resected 
tissue lndeed represented mlcroscoplc GBM cancer 
spread (Figure 7F,G). 
Hand-Held Raman Scannlng of SERS N.nopartldes Detects 
lntraventrkular Tumor Spfead. Remarkably, ln one of the 
mice. Ra man hand-held scanning using variable angles 
detected SERS signal within the right lateral ventricle 
(Figure SA,B). As confirmed by subsequent H&E and 
anti-olig-2 immunohistochemical staining. the Raman 
slgnal corresponded to a microscopic (- 1 50- 200 .um) 
duster of tumor cells in the right lateral ventricle on the 
deepest brain sections (Figure 8C.D). 
Validation and QuantifiQtion of SERS Nanopartide Ac:01111u· 
latlon wlttlin GBM Tumon. To further validate the accu-
mulation of the SERS nanopartides withln the GBM 
tumors, we performed correlation between immuno-
histochemical staining for tumor tissue and TEM ima-
ging visualizing the SERS nanoparticles. This consis-
tently showed the presence of SERS nanoparticles 
(black clrcles, corresponding to the gold core) withln 
the tumor tissue (figure 9A). To quantify the SERS 
nanopartide uptake w1thin tumors, we measured the 
gold content within tumor samples with inductively 
coupled plasma mass spectrometry (ICP-MS). Because 
KARABEBER ET AL 
the SERS nanoparticles have a gold core of defined slze, 
this method allows quantificatlon of intraturnoral SERS 
nanoparticle uptake. The result was 0.8 ± 031% 
injected dose (10) per gram tumor tissue (figure 98). 
DISCUSSION 
The detection of SERS nanopartlcles with Raman 
spectroscopy has major advantages over other molec-
ular contrast agent approaches such as nuorescence 
imaging, in that it offers not only very high sensitivlty 
but also a unique specificity of detection. SERS nano-
particles cause massive signal amplification of an 
exogenous reporter built into the nanoparticle, which 
results in a unique Raman "fingerprinr".14.38 This over-
comes disadvantages of Ouorescent molecular ima-
ging agents, where autofluorescence can often be 
limiting by creating false-positive signal. ln delicate 
surgical seenarios such as brain tumor removal elim-
inatlng any unnecessary resection of healthy tissue is 
especially important. 
Because of the diffuse pattem of GBM Invasion into 
adjacent brain tissue. it is uncertain whether a truly 
complete surgical removal of all tumor cells (and 
therefore eure) would be feasible in humans, even with 
the availability of the most sensitive imag~uidance 
technology. However. complete surgical resections are 
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Flgure S. GBM Resection wlth guld1nce by hand-held Raman scanner. (A) Photogr~phs of the lntact britin before (A 1) and 
after (A2 1nd A3) successlve tumor resectlons gulded by the hand-held Raman scanner (90• angle). When the hand-held 
Raman scanner was used at variable angles 1fter these resectlon steps, additional mlcroscopk tumor tlssue was detected 
(locatlon depicted by arrowhead ln A4). (8) SfRS Images acqulred with the Raman mlaoscope before (81) and after (82 and 
83) successlve tumor resectlons. 10 Hand-held Raman scanner verified data acquired with the Raman mlcroscope (Cl - 3). 
Angulitted scannlng with the hand-held Ra man scanner detects miaoscopic tumor in the lateral wall of the tumor bed that 
would have been mlssed otherwlse (C4). Additional resectlon was performed. and repeat angulated scannlng with the hand-
held scanner resulted in no detectable residual Raman slgnitl (CS). The resectlon bed was then processed hlstologlcally 
(red Rarnan spectra = nanopartkles detected in braln tlssue; blue Raman spectra = SERS nanopartfeie standard as control). 
feasible in other brain tumor types, especially those 
occurring in children such as, e.g., ependymomas or 
pilocytic astrocytomas.6.39.~ We deliberately chose a 
GBM model for the purpose of testing our technique in 
order to evaluate how weil it would perform in the 
mostextreme and difficult scenario. Given the homing 
mechanism of the SERS nanoparticles. which to a large 
part is relying on the "enhanced permeability and 
retention• (EPR) effe<:t, 14 the technique should also 
be applicable to other brain tumor types. 
We have recently shown that a previous generation 
of SERS nanoparticles (same dimensions but different 
Raman reporter as the S420 used here) is capable of 
KARABEBER ET AL. 
dete<:ting microscopic tumor extensions in GBM mouse 
models using orthotopic Implantation of tumor cells 
(U87fv'G and TSS43).14 However. these models do not 
faithfully recapitulate human tumors. Thus, there is the 
need to evaluate whether such nanopartides also work 
in animal models that more closely mirnie human GBM 
tumors, such as the genetically engineered RCA5-POGF-
driven/tv-a34 murine model used in this study. 
Although SERS Images acquired with a Raman mi-
croscope are promising in dete<:ting microscopic GBM 
Infiltrations, SERS imaging using a Raman microscope 
is currently not a real-time imaging method; lmaging 
requires acquisition times ln the order of minutes to 
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Flgure 6. GBM resection with guidance by the hand-held Ra man sanner and histological validation. (A) T2-welghted brain 
MRI, showlog a mass in the rlght frontal lobe. (B) Whlte light photograph of the lntact braln before resectlon, showlog a 
discoloratlon in the area of the braln correspondlng in locatlon to the MRllmage. (C) Photograph of the tumor bed after SERS 
nanoparticle-gulded resection. (0) Cranial (top) to caudal (bottom) H&E stalned hlstologlcallmages of axial brain sectlons 
after compietlon of surgery. 01 03 depict heaithy brain tissue on the medial (01 ), posterior (02), and lateral (03) walls of 
exposed tumor bed postresectlon, wlth no residua.l tumor cells detected. 
hours, depending on the desired resolution and field of 
view. Furthermore, it is not practical to scan the tumor 
resection bed at different angles, nor does the Instru-
mentation allow this. We hypothesized that a hand-
held Raman spectrometer in conjunction with SERS 
nanoparticles could solve the issues related to acquisi· 
tion speed and flexibllity of the angle, leading to a 
viable technique for real-time guidance in the operat· 
ing room. While several hand-held Raman scanners are 
available commerclally, we deliberately chose a model 
that is already used in clinical trials,31 albeit for the 
purpose of detecting "lntrinsic" Raman tlssue spectra. 
lntrinsic, i.e., nonamplllied conventional Raman spec-
troscopy has the disadvantage of requiring very long 
acquisition tim es in the order of 10- 20 s perindividual 
spectrum. Therefore, conventional intrinsic Raman 
spectroscopy is not expected to be useful for GBM 
resections in a dinlcal Setting. Herewe use the same 
hand-held scanner, however in conjunction with SERS 
nanoparticles that amplify the Raman signal by a factor 
of at least 108-fold. Thisallowed the recording of robust 
SERS nanopartfeie spectra with acquisition times as 
short as 100 ms. We cross-validated the data acquired 
with the hand-held scanner using our static Raman 
microscope, and found the hand-held scanner to have 
three major advantages over the static Raman micro-
scope: (1) lt has the potential tobe used in a dinical 
operating room. (2) lt can probe areas of interest wlth 
near real-time imaging speed. (3) Most importantly, the 
KARABEBER ET AL 
surgeon can Interrogate the operaring bed with the 
hand-held probe from any desired angle, thereby 
providing optimal coverage of the tumor resection 
bed. This allows problng of the lateral walls of the 
resection bed that are usually hidden by overlying 
brain tissue when the fixed 90° angle Raman micro-
scope is used. 
ln this study, those advantages translated into im-
proved removal of residual tumor identlfied by micro-
scopy during GBM surgery. The hand-held scannerwas 
able to identlfy, in al110 mice (n = S in group II and iii 
each), small tumor foci that were not detected on the 
Raman Images. Thls is attributable to the flexlbility of 
angulatlng the hand-held scanner to probe any area in 
the operating bed, even those located at the lateral 
margins underneath overlying normal brain tissue. 
When resection was based on the hand-held scanner 
data alone, no residual tumor cells were found in the 
walls of the resection bed on histological analysis. This 
was achieved based on the SERS nanoparticle signal, 
without using any additional "safety margin". Safety 
margins are often used in current dinical practice 
in order to remove potentially present (but not 
confirmed) microscopic tumor extensions that cannot 
be visuallzed with the naked eye. However, safety 
margins have the disadvantage of increased patient 
morbidity due to unnecessary resection of adjacent 
healthy neurological structures. Remarkably, the hand-
held Raman scanner also correctly identified the one 
VOL. 8 • NO. 10 • 9755- 9766 • 2014 
www.acsnano.org 
9761 
Residual tumor in situ 
before resection After resection Resected residual tumor 
A. 
c. 
I 
I 
D. 
Figure 7. Represenlatlve example of tumor tlssue detected only with the hand-held Sc.lnner. The tissue that was detected 
with the angulated hand-held Ra man scanner (A) and subsequently resected (Band 0) demonstrated the presence ofthe SERS 
nanopartide Raman slgnature (C), that was conf\rmed tobe tumor by transmiss Ion electron microscopy (TEM) and hlstoloqy. 
TEM showed the presence of SERS nanopartkles wlthln the resected speclrnen (E). H&E and lmmunohistochemkal stalnlng for 
tumor marker Ollg-2 conf\rmed that the resected tissue lndeed represented mlcroscopk GBM cancer spread (F and G). 
case where, unexpectedly, intraventricular tumOI' spread 
was present 
There are several possible explanations why the 
detection of GBMs with SERS nanoparticles is so robust. 
and results in the detection of microscopic tumor fod. 
We have previously shown in other mouse models of 
GBM that SERS nanoparticles can be found in lnfiltrat-
ing tumor zones, in microscopic fingerlike protrusions 
and ln satellite lesions at or beyond the macroscopic 
tumor margin.14 1t is known that nanoparticles within a 
certain size range and surface charge accumulate 
specifically in cancer tissue, but not in normal tissues 
because of mechanisms unique to tumor biology. 
These mechanisms are described by the term EPR 
effect.41 44 However, the mechanism of uptake of 
nanoparticles is in all likelihood not limited to the 
EPR effect There are other more recently discovered 
mechanisms that contribute to nanoparticle uptake 
and retention in tu mors, such as macropinocytosis.45_.6 
KARABEBER ET AL. 
Very recently, another previously unknown mechanism 
of nanoparticle delivery to tumors has been described: 
drculating white blood cells, especially monocytes, can 
take up nanopartides while they clrculate through 
blood vessels, and subsequently home to tumors.47 Thls 
is important because cellular migration across the 
blood-brain-barrier is a known phenomenon."8 Such a 
•trojan-hOI'se• transport within transmlgrating white 
blood cells41 could explain the passage of nanopartides 
across an intact blood-brain-barrier. 
One of the limitatlons of our study is that we 
performed the tumor resections on brains thal had 
been fixed in paraformaldehyde, and is therefOI'e not 
fully representative of the actual surgical environment. 
We chose an ex vivo surgical approach in order to 
achieve the highest possible accuracy in correlating 
the Raman data with the histological data. Although 
surgery performed on brain tumors in llving subjects is 
more complex, we do not foresee problems related to 
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Flgure 8. Oetection of lntnventrkular tumor spread by hand.tleld Raman scannlng. (A) Photograph showlng an anterlor vlew 
of the br~ln after complete resection gulded by the hand-held Raman scanner. (8) SERS nanoparticle spectrum (red) from 
scannlng the rlght ventrlcle for 2 s wlth 1~ la~r power at an acute angle (blue spectrum = SERS nanopartlcle standard as 
control). (C and 0) Histology of axial braln sectlons stalned wlth H&f and an~lg-2 showing clusters oftumorcells within the 
ventrlcular system.lnsets are 4 x magnlfkatlon. 
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Flgure 9. Validation ofSERS nanopartide accumulatlon wlthln G8M tumors. (A) lmmunohlstochemlstry (an~lg-2 antibody) 
and representatlve TEM Image showlng the presence of SERS nanopartldes wlthin the tumor. The area labeled "TEM" on the 
IHC sllce represents the tlssue that was exclsed and processed for TEM lmaglng. (8) Quantlfication of SERS nanoparttele 
uptake within G8M tumor tlssue via ICP-MS. Oata represent mean ± SEM (n = 3 mlce). 
imaging agent extravasation in the operating bed due 
to bleeding. Another potential Iimitation of the tech-
nique ls that depth penetration with conventional 
Raman spectroscopy imaging techniques is in the 
order of 5- 7 mm.14 
KARABEBER ET AL. 
A hand-held Raman scanner in conjunction with 
highly sensitive SERS nanoparticles such as those used 
here can serve as a near real-time intraoperative scan-
ning tool. lt provides the capability of scanning 
the operative bed from any desired angle in order to 
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examine every aspect of the tumor bed. lt therefore 
has the potential to replace other much more costly 
and time-consuming methods of intraoperative im-
age-guidance (such as MRI), while at the same t ime 
delivering higher precislon Information about the 
actual location of brain tumor cell dusters. Studies 
examining pattems of brain tumor recurrence have 
consistently shown that 80- 90% of recurrences are 
within the original treatment field, implicating residual 
tumor cells due to incomplete resection as the 
cause.9·' 0 The ability to detect and resect microscopic 
tumor remnants could result in more complete tumor 
resections and potentially increase patient survival. 
A potential Iimitation toward this goal could be that 
even though the technique presented here may allow 
for complete tumor resections to be performed in 
principle, a truly complete removal of all tumor cells 
may be prohibitive in many patients because the 
tumor has spread to crudal neurological structures. lt 
will require clinical studies to determine the benefit of 
brain tumor resections using SERS nanoparticle gui-
dance. The more complete tumor resections achleved 
with this technique are expected to increase patient 
survlval, but a potential increase in patient morbidity 
due to the increased amount of resected brain tissue 
will have to be evaluated. Other advantages of the 
presented method could be that operating tlmes 
can be decreased markedly compared to the use of 
METHODS 
Sf.RS ~ Pnplmlon. SERS nanopartldes (S420;Cabot. 
Boston, MAl are composed of spherical gold cores of approxi-
mately 60 nm ln dlameter and are coated with a monolayer 
ofthe Raman reporter 4.4'-dipyridyl and encapsulated ln a sllica 
shell of approximately 30 nm radius (totlll pattlcle stze - 120 nm). 
For lntra\leOOUS (lv) lnjectlons, panlde concentrations were 
adjusted to 28.0 nM as determined by nanopartlde tracking 
analysis (NTA) uslng the Nanosight NSSOO (Malvem. Worcester-
shire. U.K.). then suspended in 2~N-morpholino)ethanesulfonic 
aod (MES) buffet' (pH 7 3). 
(itMQtlon rrf •~ Mouse GBM Modtl. All animal experi-
ments were approved by the lnstitutional Anima! Care and 
Use Committees of Memorial Sloan Kettering Cancer Center. 
We used a genetlcally englneered glloblastoma mouse model, 
PDGF-drtven gllomas using RCAS!tv·a,"'" 9 whlch ls known to 
mirnie the biology of human glioblastomas very closely.u ·37 
OF-1 ceUs were purchased from ATCC (Manassas. VA}. Cetls 
were grown at 39 •c according to ATCC lnstructions. Transfee-
tfons were performed using Fugene 6 transfectlon kit (Roche I 
11814443001,1ndianapolls,IN) according to the manufacturer's 
lnstructlons. The 4 6 week old nestin tv-o/inkofo.arf I /pten""' 
m1ce were anesthertzed with ketamlne (0.1 mg/g) and xylazine 
(0.02 mg/g) and injected using stereotactlc fixauon deYICe 
(5toelting. Wood Dale. lU. One microliter of RCAS-roGF-8 or 
1 :1 mbcture of 4 x 1 !t RCAS POGF· B and RCAS.(re transfected 
DF-1 cells was deWvered uslng a 30 gauge needle attached to a 
Hamilton syringe. lnjections were targeted to the subventricular 
zone. coordlnates bregma 1.7 mm (antefiOf), Lat 0.5 mm (right), 
and depth 2.5 mm from the dural surface. 
Pmuf9lall MRL Four weeks after lnjection of the DF·1 cells, 
mke were lmaged with MRI to determine tumor slle and 
location for presurgical planning. MRI scans were conducted 
with a dedicated srnall animal MRI scannet conslsting of a 4.7 T 
KARABEBER ET AL. 
intraoperative MRI. Given that the SERS nanoparticles 
used here have already passed extensive cytotoxicity 
studies.32 and the hand-held scanner used here has 
already been employed in clinical trials,ll this SERS 
nanopartiefe molecular imaging-guided surgical ap-
proach holds promise for dinical translation. 
COHCLUSIOHS 
The potential of gold- silica SERS nanoparticles 
combined with a hand-held Ra man scanner to provide 
image-guided surgical resection of GBMs is demon-
strated in a transgenic murine model that closely 
recapitulates human brain tumors. Cross-validation 
with a conventional Raman microscope showed that 
both methods enabled equally sensitive Raman spec-
troscopic detection of SERS nanoparticles. While cur-
rent generations of hand-held scanners are not yet 
able to routinely acquire entire SERS Images, they have 
important advantages that are complementary and 
additive to SERS imaging Instruments: first, their form 
factor allowing their use in the operating room; second, 
rapid scanning speed afforded by the SERS amplification. 
allowing near real-time scanning; and third. ßexibility 
to probe any area of the operative bed due to variable 
tilt angles. We suggest that SERS-nanopartide-guided 
surgery using hand-held Raman detectors represents 
a highly translatable approach to fadlitate the resection 
of brain tumors and potentially other cancer typeS. 
superconductlng magnet (Bruker Biospin Corp. Bfllerica, MAl. 
gradient (Resonance Research, lnc. Blllerica, MA) with clear bore 
slle of 20 cm, maximum gradient ampUtude of 400 mT/m and 
maximum slew rate of 1300 T/{m/s) and a Bruker Avance 
electronlcs and console and IECO ampUfiers (International 
E.lectric Co. Hetsinkl, Finland). Custom made RF colls were used 
for RF I!Xdtation and detection during scanning. T2-weighted 
fast spin echo sequences (TEIT'R 50 ms/2000 ms) were em-
ployed using 4 NEX. a 256 )( 128 matrix, a 3.0 cm field-of-view. a 
sllce thickness of 100011m and a totallmaging time of - 10 mln. 
l'murgbl Prtpmtlon. The GBM bearing mice were generally 
sacrificed approxtmately 24 h after a single intravenous tail vein 
lnjec.tion wlth 5ERS nanoparticles. Blood was collected vio 
cardlac puncture, and Raman scans of the blood were obtained 
to verifythat no residual 5ERS nanopanides were present in the 
clrculatlon. A cranlotomy was performed to expose the braln, 
and brains intaet withln the skull bases were flxed in 4'11> 
paraformaldehyde for 24 h at 4 C. followed by a rinse w1th 
PB5 for 15 30 min and in 70'111 ethanol for another 24 h. Brains 
were scanned using the Raman mlaoscope and the hand-held 
scanner before every tumor resection step as descnbed below. 
Sf.RS IINglng Uslng IM lt.lmln Mkroscope. To acqulre 5ERS 
Images of the 5ERS nanopartlcle dlstributlon, we used a custo-
mlzed benchtop lnV~a Raman mlcroscope (Renlshaw, Glouces· 
tershire, U.K.) equipped Wlth a 5treaml.Jne Plus rapid lmaging 
upgrade, plezo-<ontrolled stage for micron resolved spatlal rnap-
plng, and a charge<oupled device detector wlth 1024 pixels 
(pixet si:ze: 26 11ml. spearal dispersion 1.25 cm 1/pixet and 
spectral resolutlon of - 3.7 cm ' . We used a semiconductor dlode 
near-lnfrared Iaser operating at 785 nm as the excitatlon source 
wlth a Iaser power output of - 300 mW, resulting in appraxirnately 
100 mW at the sldn surface. Ra man Images woere acqW'ed in 
the streamNne scannlng mode, using a computer-controlled x- y 
translation stage, an integratlon time of 2 s. a S )I lens (Leica, 
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8uffalo Grove, ll), 100 pm step slze. and 1 001& Iaser power. Ra man 
speara we-e analyzed Wlth w~ 3.4 Software (Renllhaw). 
SIIS DttM!oft Uslag tllt M.wHttld a-a SQM«. We used the 
M1ruRam Raman hand held sanner <B&W TEK.Inc. Newarll. OE) 
with a 785 nm excitatlon Iaser. Raman spectr.J were analyzed 
wlm B&WSpec 4.01.26 Software (B&W TEl(). For brain scanning. 
acqulsitlon Iimes of 1 2 s were used. Am. scanning was 
performed by the neurosurgeon with the hand-held probe ln 
•ts stand (delivered by B&W Tek tagether with the probe), whldl 
results in a flxed 90° angle. Subsequently, the probe was 
removed from the stand and variable angle sanning was 
performed, in order to slmulate the actual cfinlcal scenarlo. 
Holding the probe ln hls hands, the neurosurgeon carefully 
performed raster-scanning of the resectlon bed, at me optimal 
focal distance of approxlmately S mm from the tissue ofinterest. 
llhtologlc;ll AMiysls. Brain tissues after tumor resections 
were embedded in paraffin. Hernatoxylin and eosin stalnlng 
and lmmunohlstoc:hemlstry (IHC) staining were performed on 
S pm-mkk sectlons. The Discovery XT blomarker platform 
(Ventana, Tucson, Al) was used for IHC staining of Ollg2. 
Antigen was retrieved uslng the heat-lnduced antlgen unmask 
lng technique in cltrate-based buffer (pH 6.0). Antl.OIIg-2 (1 :300, 
A89610, Millipore, Temecula, CAl and biotin-labeled antl-rabbit 
antlbody ( 1:300, 8A·1 000, Vector Laboratories, Burlingame, CA) 
were used as the pnrnary and secondary antibodles, respec 
ovely. Streptavidm blotin peroxidase was visuallzed by the 
Discovery OA8 map detection klt (760-124, Ventana). 
Proctdurt fOf TEM IRin Tluut Slmplt Prepir1tlon. Brain tissue 
samples were fixed ln 2.5'1& glutaraldehyde/2% paraformalde· 
hyde in cacodylate buffer, rinsed in buffer and post flxed ln 2'1& 
osmium tetroxlde for 1 h. The samples ware rlnsed ln double 
dlstllled water, followed by a graded series of aqueous ethanol 
solutlons (SO%, 75'1&, 95'1& to 1 001& alcohol), followed by propy 
lene oxlde. and overnight 1:1 propytene oxide/PolyBed 812. The 
samples were embedded in Poly/Bed 812 and cured ln a 60 "C 
oven. Ultrathin sectlons were obtained with a Relchert Ultracut 
S mlaotorne. Sectlons were stained with uranyl acetate and 
Iead dtrate and photographed uslng a Jeol 1200EX transmls· 
slon electron mlaoscope. 
lncluctiYtly CGuplt4 ,._.. Mm ~ (KP~. Braln tu 
mor tissue samples of known rnasses were taken up ln 2 ml of 
freshly prepared oquo reglo (I :3 ratlo of concentrated nltrk add 
and hydrochlorlc acld) and heated to dryness. Thls process was 
repeated until the samples could fully dlssolve ln the acldk 
solutlon. The samples were then dissolved in 05 ml of oquo 
reglo and subsequently diluted with water to 75 mL The 
samples were then analyzed at the Brooklyn College Envlron 
mental Seiences Analytical Center on a PerkinEimer Ban DRC -i! 
ICP-MS Instrument and referenced to a HAuCI4-derived cahbra· 
tlon curve. 
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